LQAI0.730%
as of Sep 2
DXCM
GrowthDEXCOM INC
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
Close · 3M
+45.70%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals19
Win rate79% (15/19)
Avg buy return+13.17%
LQAI · Weight decrease · 2d
weight 0.790% → 0.730% (-0.060 pp)·stock up 3.2% in the 30 days before
Sep 2·entry $89.69·now $89.71
+0.02%
since Sep 2
LQAI · Weight decrease · 2d
weight 0.800% → 0.770% (-0.030 pp)·stock up 18.9% in the 30 days before
Aug 26·entry $88.96·now $89.71
+0.84%
since Aug 26
LQAI · Weight increase · 2d
weight 0.750% → 0.780% (+0.030 pp)·stock up 20.2% in the 30 days before
Aug 19·entry $89.88·now $89.71Fresh
-0.19%
since Aug 19
LQAI · Weight decrease · 3d
weight 0.790% → 0.750% (-0.040 pp)·stock up 15.8% in the 30 days before
Aug 17·entry $88.76·now $89.71
+1.07%
since Aug 17
LQAI · Accumulation · 5d
weight 0.730% → 0.760% (+0.030 pp)·stock up 15.1% in the 30 days before
Aug 14·entry $89.75·now $89.71Fresh
-0.04%
since Aug 14
LQAI · Accumulation · 5d
weight 0.730% → 0.780% (+0.050 pp)·stock up 25.8% in the 30 days before
Aug 13·entry $91.48·now $89.71Fresh
-1.93%
since Aug 13
LQAI · Accumulation · 5d
weight 0.730% → 0.790% (+0.060 pp)·stock up 22.5% in the 30 days before
Aug 12·entry $90.80·now $89.71Fresh
-1.20%
since Aug 12
LQAI · Weight increase · 4d
weight 0 → 0.780% (new)·stock up 17.3% in the 30 days before
Aug 11·entry $89.53·now $89.71Fresh
+0.20%
since Aug 11
LQAI · Weight increase · 3d
weight 0 → 0.770% (new)·stock up 16.9% in the 30 days before
Aug 10·entry $87.65·now $89.71Drifting
+2.35%
since Aug 10
LQAI · Weight increase · 2d
weight 0 → 0.740% (new)·stock up 16.1% in the 30 days before
Aug 7·entry $84.75·now $89.71Drifting
+5.85%
since Aug 7
LQAI · New entry · 1d
weight 0 → 0.730% (new)·stock up 12.1% in the 30 days before
Aug 6·entry $83.02·now $89.71Drifting
+8.06%
since Aug 6
AIVL · Exit · 1d
weight 0.342% → 0 (exited)·stock up 21.2% in the 30 days before
Jul 31·entry $83.45·now $89.71
+7.50%
since Jul 31
AIVL · Weight increase · 3d
weight 0.324% → 0.342% (+0.017 pp)·stock up 7.4% in the 30 days before
Jul 29·entry $75.14·now $89.71Chased
+19.39%
since Jul 29
AIVL · Weight increase · 2d
weight 0.324% → 0.337% (+0.013 pp)·stock up 6.7% in the 30 days before
Jul 28·entry $74.85·now $89.71Chased
+19.85%
since Jul 28
AIVL · Weight decrease · 5d
weight 0.355% → 0.324% (-0.031 pp)·stock up 2.3% in the 30 days before
Jul 23·entry $70.48·now $89.71
+27.28%
since Jul 23
AIVL · Weight decrease · 4d
weight 0.355% → 0.329% (-0.026 pp)·stock up 3.4% in the 30 days before
Jul 22·entry $71.43·now $89.71
+25.59%
since Jul 22
AIVL · Weight decrease · 3d
weight 0.355% → 0.345% (-0.010 pp)·stock up 3.1% in the 30 days before
Jul 21·entry $74.75·now $89.71
+20.01%
since Jul 21
AIVL · Weight decrease · 2d
weight 0.355% → 0.348% (-0.007 pp)·stock up 6.3% in the 30 days before
Jul 20·entry $75.69·now $89.71
+18.52%
since Jul 20
+23.35%
since Jul 15
+21.03%
since Jul 14
+17.50%
since Jul 13
+19.68%
since Jul 10
+22.86%
since Jul 9
+21.13%
since Jul 8
+21.94%
since Jul 7
+23.94%
since Jul 6
+25.91%
since Jul 2
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of May 2
The AI ETFs, specifically AIVL, are showing a recent trend of decreasing their weight in Dexcom. This observed selling activity aligns with the framework's 'Fail' verdict, which primarily stems from concerns regarding a lack of sufficient margin of safety at the current price and incomplete financial health data.
- Circle of CompetenceThe unit economics of continuous glucose monitoring, with recurring sensor sales for a chronic condition, appear sufficiently stable and predictable for reasonable ten-year cash flow projections.
- Economic MoatDexcom benefits from a durable economic moat comprised of strong brand recognition, patient and provider switching costs, and regulatory and patent barriers to entry in the medical device market.
- ManagementThe provided financial data is insufficient to assess management's candor, capital allocation discipline, or their personal stake in the company.
- Financial HealthDespite a strong recent ROE, the absence of 10-year ROE data, operating margins, detailed debt figures, and owner earnings prevents a comprehensive assessment against the framework's financial health criteria.
- Margin of SafetyThe current valuation multiples for Dexcom (PER 28.38, PBR 9.43, EV/EBITDA 22.39) appear high, making it difficult to identify a defensible discount to intrinsic value for a sufficient margin of safety.
Dexcom operates within a predictable circle of competence and possesses a strong economic moat, suggesting a high-quality business. However, the framework's assessment is hindered by insufficient data to evaluate management and key aspects of financial health, leading to a 'Fail' on that stage. Moreover, the current valuation does not present a clear margin of safety, resulting in an overall 'Fail' verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.